A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Eligible participants must be registered patients at a participating site. Participation in the study will last about 260 weeks.
Conditions studied
Obesity
About this study
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Eligible participants must be registered patients at a participating site. Participation in the study will last about 260 weeks.
Interventions
- Drug: Tirzepatide — Administered SC
- Other: Standard of Care — Standard of care
Primary outcomes
- Percent Change from Baseline in Body Weight (Baseline, 24 months)
Eligibility information
Study locations
- P91604 St John's Medical Centre, Altrincham, WA14 1PF United Kingdom
- P89008 Ashton Medical Group, Ashton-under-Lyne, OL6 6EW United Kingdom
- Y02319 SSP Bolton General Practice, Bolton, BL1 4TH United Kingdom
- P83012 Tower Family Healthcare, Bury, BL9 0NJ United Kingdom
- P91014 Washway Road Medical Centre, Cheshire, M33 7SS United Kingdom
- P88007 Cheadle Hulme Medical Group (was Cheadle Hulme Health Centre) (Bridge House), Cheshire, SK8 5LL United Kingdom
- Y02790 SSP Bolton Medical Centre, Great Lever, BL3 6PY United Kingdom
- P89002 The Brooke Surgery, Hyde SK14, SK14 1AT United Kingdom
- P84035 Bodey Medical Centre, Manchester, M14 6WP United Kingdom
- P84630 The Arch Medical Practice, Manchester, M15 5TJ United Kingdom
Showing 10 of 30 reported sites. See the official listing for all locations.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.